Design Therapeutics, a clinical-stage biotech company, will announce data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2, a treatment for Friedreich’s ataxia, on May 18, 2026. The company will host a live webcast and conference call to discuss the trial results, which are important for advancing treatment options for this genetic disease. This event marks a key milestone as the company continues to develop gene-targeted therapies for serious degenerative diseases. Investors and interested parties can access the webcast via the company’s website, with the recording available for 30 days afterward.
Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared...
The iShares 20+ Year Treasury Bond ETF (TLT) saw $122 million in outflows last week amid rising US bond yields driven by higher inflation and hawkish Federal Reserve signals. April's inflation data showed consumer prices jumping to 3.8% and producer ...
A Colorado bankruptcy judge temporarily closed then agreed to reopen what could be the largest Chapter 11 case in state history involving 440,040 veterans from the Camp Lejeune Justice Act (CLJA) Settlement Club. The case concerns a $44.4 billion set...
Dianthus Therapeutics' Chief Financial Officer sold 8,224 shares of the company, generating approximately $739,000 from the transaction. This insider sale could indicate the CFO's personal financial decision or a strategic move, but it may raise ques...
Hyperliquid founder Jeff Yan visited Washington, D.C. to engage with U.S. policymakers amid the Clarity Act's progress. The discussions focused on introducing regulated onchain derivatives markets in the U.S., reflecting growing crypto literacy among...
